Global: Glaxo, Pfizer JV opens HIV pipeline to generic companies

ViiV Healthcare, GlaxoSmithKline and Pfizer's joint venture company for AIDS drugs, is opening its entire product line-up to generic drugmakers working in the world's poorest countries. The announcement, on the eve of next week's international AIDS conference in Vienna, means generic companies will be able to obtain royalty-free voluntary licences for all current ViiV products, as well as products still in development.